These two prospective studies validating over 1000 patients [48,61] showed that ExoDx (AUC 0.71 and AUC 0.70, respectively) was better at predicting clinically significant PCa at first biopsy than existing risk calculators and PCPT-RC (AUC 0.63), ERSPC-RC (AUC 0.58) and PSA alone (AUC 0.58). The gene discussed is KLK3; the disease is posterior cortical atrophy.